Physician profile
John Johnson
NPI 1003413808
$8,390.91
in general payments reported to CMS, 2019-2025
25 companies · $1,333 in 2025
The $1,333 reported for 2025 was more than what 86% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,847 · 2022: $2,106 · 2023: $1,860 · 2024: $1,246 · 2025: $1,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,426 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,426.31 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,315.32 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,258.79 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $788.73 | 2021-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $754.15 | 2021-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Lundbeck LLC | $682.02 | 2021-2025 | Rexulti |
| Sunovion Pharmaceuticals INC. | $573.96 | 2021-2022 | |
| Alkermes, INC. | $556.59 | 2021-2024 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $530.26 | 2021-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Avanir Pharmaceuticals, INC. | $305.68 | 2021-2022 | |
| Corium, LLC | $303.63 | 2022-2024 | Azstarys |
| Axsome Therapeutics, INC. | $248.34 | 2022-2025 | Auvelity, Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $161.49 | 2021-2023 | Trintellix |
| Neurocrine Biosciences, INC. | $139.70 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $118.81 | 2024-2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $117.51 | 2024-2025 | Cobenfy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $108.73 | 2021-2023 | Loreev Xr, Sertraline Hcl |
| Idorsia Pharmaceuticals US INC | $76.15 | 2022-2024 | Quviviq |
| Noven Therapeutics, LLC | $73.13 | 2023-2024 | Xelstrym, Secuado |
| Indivior INC. | $69.93 | 2021-2024 | Perseris |
| Ironshore Pharmaceuticals INC. | $62.93 | 2022-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $50.55 | 2024-2025 | Qelbree |
| Collegium Pharmaceutical, INC. | $32.18 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $26.84 | 2021 | |
| Merck Sharp & Dohme LLC | $20.07 | 2023 | Belsomra |
| Jazz Pharmaceuticals INC. | $15.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.